Physician profile
Phillip Poulos
NPI 1053422675
$1,324.77
in general payments reported to CMS, 2019-2025
13 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $66.72 · 2021: $162 · 2022: $338 · 2023: $272 · 2024: $169 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $520.38 | 2019-2025 | Trelegy Ellipta |
| Viiv Healthcare Company | $239.50 | 2022-2025 | Dovato, Cabenuva, Apretude |
| Novo Nordisk INC | $178.95 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $75.48 | 2019-2025 | |
| Dexcom, INC. | $68.40 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $55.07 | 2019 | |
| Amgen INC. | $41.76 | 2022-2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $38.46 | 2022-2023 | |
| Astellas Pharma US INC | $28.22 | 2019 | |
| Lilly USA, LLC | $26.32 | 2022 | |
| Abbott Laboratories | $19.34 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $18.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.89 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Poulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.